Roche’s faricimab meets primary endpoint in DME trial

Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more

Buying into the independent optometry dream

As the current economic climate prompts optometrists to reconsider practice valuations, exit plans and buyer interest, RHIANNON BOWMAN reflects on where opportunities lie for the next generation of independent practice owners. Read more